# US 2008/0287356 A1 · Chimeric Proteins, Their Preparation and Pharmaceutical Compositions Containing Them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287356 A1
- Document ID: US20080287356A1
- Status: Published application
- Kind: A1
- Application number: 11/911,252
- Filed: 2006-04-10
- Published: 2008-11-20
- Earliest claimed: 2005-04-11
- Assignees: Yeda Research and Development Co. Ltd.
- Inventors: David Wallach; Elena Appel
- Web page: https://patentgrep.com/patent/US20080287356A1

## CPC

- C07K 14/24: from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/02: Local antiseptics
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/50: containing protease site
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a chimeric protein comprising a cell-targeting agent and a Yersinia outer protein, connected by a translocating polypeptide. The invention further relates to the preparation and use of such chimeric protein.

## Claims

### Claim 1

A chimeric protein comprising the amino acid sequence of a cell-specific targeting agent and the amino acid sequence of a Yersinia outer protein (Yop) connected by a polypeptide enabling translocation of the chimeric protein, or of a fragment thereof, from the endosome to the cytosol of a target cell.

### Claim 2 (depends on 1)

A chimeric protein according to claim 1, wherein the cell-specific targeting agent is the extracellular portion of a receptor of a ligand expressed on the surface of the target cell.

### Claim 3 (depends on 2)

The chimeric protein according to claim 2, wherein the cell-specific targeting agent is the extracellular portion of a TNF/NGF receptor.

### Claim 4 (depends on 3)

The chimeric protein according to claim 3, wherein the extracellular portion of a TNF/NGF receptor is TNF binding protein 1 (TBP-1).

### Claim 5 (depends on 3)

The chimeric protein according to claim 3, wherein the extracellular portion of a TNF/NGF receptor is TBP-2.

### Claim 6 (depends on 1)

The chimeric protein according to claim 1, wherein the Yop is YopP.

### Claim 7 (depends on 6)

The chimeric protein according to claim 6, wherein YopP has reduced or non-apoptotic activity and is selected from YopP serogroups O: 3, O: 9 and O: 8 mutated in the Arginine-143 residue.

### Claim 8 (depends on 1)

The chimeric protein according to claim 1, wherein the polypeptide enabling translocation includes the Pseudomonas exotoxin translocation domain or a fragment thereof.

### Claim 9 (depends on 8)

The chimeric protein according to claim 8, wherein the fragment of the Pseudomonas exotoxin translocation domain is deficient in the last α-helix domain (F).

### Claim 10 (depends on 8)

The chimeric protein according to claim 8, wherein the fragment of Pseudomonas exotoxin translocation domain, herein designated PEIItr, corresponds to the amino acid sequence of Pseudomonas aeruginosa exotoxin in FIG. 3 (SEQ ID NO: 3).

### Claim 11 (depends on 1)

The chimeric protein according to claim 1, comprising one or two furine cleavage sites.

### Claim 12 (depends on 11)

The chimeric protein according to claim 11, wherein one furine cleavage site is located at the N-terminus of the polypeptide enabling translocation, and one furine cleavage site is located at the N-terminus of the Yop protein.

### Claim 13 (depends on 11)

The chimeric protein according to claim 11, wherein one furine cleavage site is the furine cleavage site of the Difteria toxin.

### Claim 14 (depends on 13)

The chimeric protein according to claim 13, wherein the furine cleavage site has the amino acid sequence RVRR, herein designated DT.

### Claim 15 (depends on 14)

The chimeric protein according to claim 14, wherein the chimeric protein consists of TBP-1, the translocation domain fragment of Pseudomonas aeruginosa exotoxin PEIItr, the furine cleavage site DT, and YopP, herein designated TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment or salt thereof.

### Claim 16 (depends on 1)

The chimeric protein according to claim 1, wherein the target cell is a lymphoid cells.

### Claim 17 (depends on 16)

The chimeric protein according to claim 16, wherein the target cell is a macrophage.

### Claim 18 (depends on 16)

The chimeric protein according to claim 16, wherein the target cell is a monocyte.

### Claim 19 (depends on 1)

The chimeric protein according to claim 1, wherein the target cell is an epithelial cell.

### Claim 20 (depends on 1)

A DNA sequence encoding a chimeric protein according to claim 1.

### Claim 21 (depends on 20)

The DNA sequence according to claim 20, further encoding a signal peptide for secretion in eukaryotic cells.

### Claim 22 (depends on 20)

An expression vector comprising the DNA sequence according to claim 20.

### Claim 23 (depends on 22)

The expression vector according to claim 22, wherein the DNA is functionally linked to a promoter having an activity which is independent of NF-κB.

### Claim 24 (depends on 23)

The expression vector according to claim 23, wherein the promoter is EF-1α.

### Claim 25 (depends on 22)

A host cell comprising an expression vector according to claim 22.

### Claim 26 (depends on 25)

The host cell according to claim 25, wherein the cell is an eukaryotic cell selected from HeLa, CHO, 293, Yeast, and insect cells.

### Claim 27 (depends on 25)

The host cell according to claim 25, wherein the cell is a prokaryotic cell.

### Claim 28 (depends on 1)

A method of producing a chimeric protein according to claim 1, comprising culturing a host cell comprising an expression vector comprising the DNA encoding said chimeric protein, and isolating the chimeric protein produced.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein or fragment thereof.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a chimeric protein according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The pharmaceutical composition according to claim 30, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment, or salt thereof.

### Claim at position 32

32-41. (canceled)

### Claim 42 (depends on 1)

A method for the treatment of a disease in which the ligand of the TNF/NGF receptor is involved in the pathogenesis or in the course of said disease comprising administering to a subject in need a therapeutically effective amount of a chimeric protein according to claim 1.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the ligand of TNF/NGF receptor is TNF.

### Claim 44 (depends on 42)

The method according to claim 42, wherein the disease is selected from the group consisting of malaria, sepsis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer.

### Claim 45 (depends on 42)

The method according to claim 42, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment or salt thereof.

### Claim 46 (depends on 1)

A method for the treatment of a disease in which activated macrophages or monocytes are involved in the pathogenesis or in the course of said disease, comprising administering to a subject in need a therapeutically effective amount of a chimeric protein according to claim 1.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the disease is selected from the group consisting of septic shock, rheumatoid arthritis, ankylosing spondylitis, psoriasis, amyotrophic lateral sclerosis, insulin-dependent diabetes mellitus, graft-versus-host disease, and sickle cell anemia.

### Claim 48 (depends on 46)

The method according to claim 46, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment or salt thereof.

### Claim 49 (depends on 1)

A method for the treatment of a disease in which NF-κB activation is involved in the pathogenesis or the in course of said disease, comprising administering to a subject in need a therapeutically effective amount of a chimeric protein according to claim 1.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the NF-κB activation is induced by NIK via the canonical pathway.

### Claim 51 (depends on 48)

The method according to claim 48, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment or salt thereof.

### Claim 52

A method of reducing abnormal expression of a ligand on the cell surface in a target cell comprising exposing the cell to a chimeric protein comprising the extracellular portion of a receptor of the ligand expressed on the surface of the target cell and Yop connected by a polypeptide enabling translocation of the chimeric protein, or of a fragment thereof, from the endosome to the cytosol of the cell.

### Claim 53 (depends on 52)

The method according to claim 52, wherein the ligand is TNF.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the polypeptide enabling translocation is PEIItr.

### Claim 55 (depends on 52)

A method according to claim 52, wherein the cell is exposed to the chimeric protein in vitro.

### Claim 56 (depends on 52)

A method according to claim 52, wherein the cell is exposed to the chimeric protein in vivo

### Claim 57 (depends on 49)

The method according to claim 49, wherein the cell is a macrophage or monocytic cell.

### Claim 58 (depends on 49)

The method according to claim 49, wherein the chimeric protein is TBP-YopP, or a mutein, variant, fusion protein, functional derivative, fragment or salt thereof.
